Immuno-Oncology

Progress your preclinical immunotherapeutics with CrownBio’s comprehensive In Vivo Immunotherapy Translational Technology Platform

oncology-magnifyglass.png

Immunotherapy represents the most promising new cancer treatment approach since the first development of chemotherapies, and has come of age as a treatment paradigm with multiple recent approvals for checkpoint inhibitors such as anti-PD-1, anti-PD-L1, and anti-CTLA-4 agents across a range of cancer types.

While immunotherapy demonstrates an extremely promising treatment option for cancer patients, advancements in the field have inevitably uncovered subsequent challenges and barriers to further development. Appropriate preclinical models (particularly those with functional immunity) are required to overcome these hurdles, and help progress new immunotherapeutics into the clinic.

CrownBio understands that one model will not fit all client research needs across this wide ranging therapeutic area. Our In Vivo Immunotherapy Translational Technology Platform therefore provides a comprehensive and varied selection of immuno-oncology preclinical models:

CAR-T Therapy Evaluation

Utilize our extensive collection of 2,500 HuPrime® Patient-Derived Xenograft (PDX) models or our MiXeno™ platform of transient human immunity in mice to evaluate novel CAR-T therapies


Humanized Models

Murine Efficacy/PD Models

  • Syngeneic tumor models provide a valuable system for assessing new single agent and combination immunotherapies within mice with fully competent immunity, and for the fast-track, large-scale, staggered, in vivo screening of compounds
  • MuPrime™ murine allograft models combine the improved predictive power of GEMM/carcinogen-induced models with an operational simplicity, consistency, and robust growth for pharmacology research, incuding efficacy and PD assessment

Contact us today for free expert advice on choosing the right preclinical model to progress your immuno-oncology research.